Bionic Eyes: retinal implants and the quest for enhanced vision

This piece surveys how electronic vision is moving from science fiction to reality, focusing on retinal implants and brain-based approaches. It outlines the history of early devices such as Retina Implant AG and Argus II, their limitations and discontinuations, and modern progress like ReVision and Prima, including 81% central vision restoration in a clinical trial. It also discusses ethical considerations about risk to residual vision and the potential for 'super-human' features. Original publisher: Nature.

• Retinal implants emerged two decades ago; rudimentary vision and frequent device failures; Retina Implant AG closed in 2019.
• Argus II obtained FDA authorization in 2013 but was discontinued in 2019 due to modest results.
• Prima device restored functional central vision in 81% of patients and is authorised in 30 European countries.
• Future directions include external cameras with occipital cortex stimulation and potential capabilities beyond visible spectrum, alongside stem cell alternatives.

Overview

The article surveys the dawning reality of enhanced, electronic vision, tracing a path from early retinal implants to newer brain-implant approaches. It begins with a look back at retinal blindness therapies and the first devices that attempted to substitute missing light-sensing cells. The central theme is that while early implants offered only rudimentary vision, steady progress—both in hardware and surgical technique—has opened the door to more substantial restoration and even augmentation of human sight. The piece also frames the ethical questions that accompany these innovations, especially as devices offer increasing functionality and the possibility of features beyond normal human vision.

Historical devices and their challenges

Early efforts to fix retinal blindness by connecting an implant to surviving retinal cells began more than twenty years ago. One of the first devices, developed by Retina Implant AG, used a light-sensing chip placed under the damaged retina. This chip connected with remaining healthy retinal cells, transmitting signals to the brain via the occipital cortex. Surgery was extensive, taking around eight hours and requiring a power receiver to be implanted behind the ear, with a wire threading beneath the skin to reach the chip. The vision produced by these implants was limited, often consisting of flashes that roughly mapped the shape of observed objects. Device longevity was another problem, with implants breaking over time likely due to rapid eye movements and corrosive internal fluids. Retina Implant AG eventually ceased operations in 2019, citing a lack of medical progress as a major factor.

The other major early device, Argus II, paired a glasses-mounted camera with a retinal chip. The camera’s images were translated into electrical signals sent wirelessly to the chip, which stimulated remaining retinal cells via an array of 60 electrodes. Despite initial promise and FDA authorization in 2013, Argus II failed to deliver sufficiently compelling results and was discontinued in 2019. These early efforts collectively highlighted the significant hurdles in achieving meaningful, durable restoration of vision through retinal prosthetics, including issues with resolution, stability, and long-term device reliability.

Newer approaches and evolving strategies

Despite these setbacks, researchers continued to pursue artificial vision, exploring strategies that bypass retinal degeneration and directly stimulate the brain. A newer paradigm uses external cameras to wirelessly deliver both power and image data to a chip implanted in the occipital cortex. This approach aims to evoke perception by directly stimulating the brain’s visual areas, potentially helping patients with retina or optic nerve diseases. However, the reduction of high-resolution information through the natural retina pathway means that the resulting vision may lack the sharpness of normal sight, and the exact limits of achievable resolution remain uncertain.

One company in this space, Belgium-based ReVision Implant, plans to begin its first human clinical test in October 2026, signaling continued industry investment in brain-implant strategies. Another approach involves spectacles that transmit both images and power to a surgically implanted subretinal chip via an infrared signal. The Prima device embodies this concept, having been tested in dry age-related macular degeneration. In a small clinical trial, Prima restored functional central vision to 81% of patients, enabling reading of letters, numbers, and words. It is now authorised in 30 European countries. The emphasis on AMD matters because it is far more common than inherited retinal diseases, making Prim a more attractive target for investors, even as the surgery to implant a subretinal chip remains high risk and non-zero.

Qualities and potential capabilities

Because these devices relay visual information electronically, the potential to extend functionality exists. Prima already offers optical zoom, and there have been proposals for image sharpening and other enhancements. In the longer term, researchers anticipate the possibility of devices that can see beyond visible light, including near-infrared capabilities that enable thermal imaging or night vision. Although such capabilities have been explored in primates, they will depend on significant advances in both artificial vision hardware and neural processing to become practically relevant.

Ethical questions and competing approaches

Ethical concerns cluster around informed consent, patient risk, and the balance of potential benefits against diminished peripheral vision for AMD patients. The article notes that while AMD patients often retain peripheral vision, the risk of serious adverse events from complex implant surgeries must be weighed against possible gains. In parallel to prosthetic approaches, stem cell therapies are advancing and could eventually overtake retinal prosthetics if risks related to cell survival, integration, and long-term function can be overcome. The broader context asks whether these technologies will merely restore sight or also significantly augment human perception, and what measures ensure safety and equity across patient populations.

Future horizons and practical reality

Looking forward, the article emphasizes that current biomaterial and electrical challenges still confine retinal prostheses to limited, rudimentary restoration. Yet the field is rapidly evolving, with ongoing trials and new devices approaching clinical reality. The tension between promising capabilities and real-world safety remains a guiding theme, as does the ethical imperative to ensure that innovations offer meaningful benefits without exposing patients to disproportionate risk. As the science advances, experts expect a blend of devices—brain-based implants, external camera systems, and biomolecular therapies—to shape the future of vision restoration, with patient safety, accessibility, and ethical governance at the forefront of development.

Conclusion

The article portrays a field in transition, from early, limited retinal implants to contemporary, multichannel strategies that engage the brain directly or pair external hardware with implanted chips. While the prospect of enhanced or even super-human vision is intriguing, the practical barriers—technological, surgical, and ethical—remain formidable. Yet the ongoing clinical trials, regulatory approvals across Europe, and upcoming tests signal a dynamic era in vision restoration, where converging technologies and careful governance may redefine what is possible for people living with retinal disease.